SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum driven by a newly announced collaboration with NVIDIA to integrate its QNX safety-critical OS into advanced edge AI systems, fueling a community-led surge in retail interest and trending status. Investors are increasingly optimistic about the companys turnaround, pointing to growing royalty backlogs, cybersecurity demand, and the stock's recent break past key resistance levels as signs of a long-awaited revaluation.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is currently trending amid a significant strategic shift as the company acquires Brazil's Serra Verde Group in a transaction aimed at securing a non-Asian source for key magnetic rare earth elements. While investors and market analysts are actively debating the potential for long-term supply chain dominance and government-backed infrastructure status, the stock is seeing heightened volatility due to concerns over share dilution and the aggressive positioning of short sellers.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility and retail interest driven by an executive order to fast-track psychedelic research, which market participants view as a significant catalyst for ibogaine-based treatments. The community is actively debating the stock's potential for a massive short squeeze given its exceptionally low float, while cautious traders warn of the risks associated with micro-cap volatility and the potential for aggressive dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing high volatility as investors weigh strong quarterly earnings and aggressive share buybacks against cautious forward guidance and the departure of a long-standing board member. The community remains deeply divided, with many retail traders actively buying the dip, while others express concerns over institutional selling pressure and potential downside risks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is currently garnering significant attention as retail and institutional investors alike speculate on a potential buyout or major partnership, driven by excitement over the firm's oncology pipeline and positive clinical trial data. Community sentiment is highly polarized, with optimistic long-term holders highlighting upcoming trial milestones and regulatory progress, while vocal skeptics point to the stock's long-term performance and historical dilution as reasons for caution.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing significant volatility as investors react to a sudden leadership shakeup involving the resignation of the CEO and CFO, alongside ongoing concerns about delayed power milestones and the search for an anchor tenant. While some community members are treating the pullback as a buying opportunity given the project's long-term scale and infrastructure potential, others are increasingly skeptical, pointing to the lack of revenue and the potential for further downside before stabilization.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following a strategic announcement to redomicile in the U.S. and resolve tax-related concerns, effectively neutralizing a recent short-seller report. The community is actively debating the stock's potential for a short squeeze and long-term valuation shifts as investors shift focus toward upcoming commercial manufacturing milestones and institutional accumulation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors react to a large upsized stock offering intended to fuel data center expansion and debt repayment, fueling community debate over the impact of dilution versus the company's long-term growth potential in AI infrastructure. Despite the share issuance, bullish sentiment remains strong as traders highlight the firm's strategic focus on securing power for hyperscale data centers and anticipate upcoming announcements regarding lease agreements in Kentucky.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is trending as the market reacts to an executive order aimed at fast-tracking psychedelic drug research for veterans and mental health, fueling speculation about clinical acceleration and potential pharmaceutical partnerships for the company's BPL-003 candidate. Community sentiment is divided between optimism regarding recent pipeline milestones and clinical validation versus frustration over historical share dilution and persistent intraday price weakness.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is surging following a successful Phase 3 trial readout for its psilocybin-based treatment, confirming strong efficacy and safety profiles for treatment-resistant depression. The community is actively debating the stock's potential as a first-mover in the psychedelic space while closely monitoring a new secondary offering that is driving significant volatility and liquidity shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$LLY continues to aggressively expand its oncology footprint — multiple myeloma alone represents a ~$40B+ global market opportunity, and the company is clearly signaling intent to compete at the highest level of treatment innovation. 
 
The strategic angle here is platform expansion: if their in vivo / next-gen biologics approach continues to progress, it doesn’t just stay in late-line settings — it potentially moves into earlier treatment lines, which is where the real revenue scale sits. 
 
This is no longer a single-market story. Lilly is positioning across multiple large therapeutic areas, with oncology first, and potential spillover into IBD next ($SYRE watchlist relevance). 
 
For context, $JNJ and $ABBV remain dominant incumbents in oncology and immunology respectively, but the competitive pressure is increasing as Lilly scales pipeline ambition across multiple $100B+ markets (obesity, oncology, immunology).

StockTwits Web

Lilly(Eli) & Co

Spyre Therapeutics Inc

Johnson & Johnson

Abbvie Inc

 continues to aggressively expand its oncology footprint — multiple myeloma alone represents a ~$40B+ global market opportunity, and the company is clearly signaling intent to compete at the highest level of treatment innovation. 
 
The strategic angle here is platform expansion: if their in vivo / next-gen biologics approach continues to progress, it doesn’t just stay in late-line settings — it potentially moves into earlier treatment lines, which is where the real revenue scale sits. 
 
This is no longer a single-market story. Lilly is positioning across multiple large therapeutic areas, with oncology first, and potential spillover into IBD next (

 remain dominant incumbents in oncology and immunology respectively, but the competitive pressure is increasing as Lilly scales pipeline ambition across multiple $100B+ markets (obesity, oncology, immunology).

Page Conan

@BottomFisher_ posted message on wrong board. Responding to those hoping LLY would acquire IOVA.

StockTwits for iOS

 posted message on wrong board. Responding to those hoping LLY would acquire IOVA.